Radiopharmaceuticals in prostate cancer – PSMA Theranostics (Episode 2 of 2)

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr Koo is an active member of multiple societies and serves on the Scientific Program Committee for the Radiological Society of North America, Nuclear Radiology Certifying Exam Committee for the ABR, and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).  He is also Chair of the Prostate Cancer Working Group at the SNMMI and was a member of the RADAR I and II working groups. Dr Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, European Journal of Nuclear Medicine and Molecular Imaging, Urology, and Journal of the American College of Radiology.  

Following a residency at Mt. Sinai Hospital in New York City, Dr Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr Dorff serves as an associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology. She has lectured on prostate and bladder cancer treatment nationally and internationally and has presented her research at national meetings. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and immunotherapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.